Olorinab (APD371)

Drug Candidate for Treatment of Pain

Olorinab (APD371) is an orally available, peripherally acting, highly-selective, full agonist of the cannabinoid type 2 receptor (CB2). Olorinab is an internally discovered investigational drug candidate that Arena is exploring for development in several indications, including visceral pain. This compound, through its selectivity for CB2, is designed to provide pain relief without psychotropic effects and without the potential for dependence or abuse.


We have completed a randomized, open-label Phase 2a clinical trial to evaluate the safety, tolerability and pharmacokinetics of two dose levels of olorinab.  Phase 2b planning is ongoing.

Drug Candidate Disease Area Target Status Retained Rights
Olorinab (APD371) GI Pain CB2 Agonist Phase 2b planning ongoing Worldwide

Drug Candidate Olorinab (APD371)
Disease Area GI Pain
Target CB2 Agonist
Status Phase 2b planning ongoing
Retained Rights Worldwide

Olorinab (APD371) has not been approved by the US Food and Drug Administration or any other regulatory agency.